Results 11 to 20 of about 6,357 (207)

Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. [PDF]

Nephrology (Carlton)
ABSTRACT Aim Efepoetin alfa, a novel long‐acting erythropoietin (EPO)‐hybrid Fc fusion protein, represents a promising erythropoiesis‐stimulating agent (ESA) for addressing anaemia in chronic kidney disease (CKD) patients. This Phase 3 trial was to assess the efficacy and tolerability of subcutaneous efepoetin alfa in comparison to subcutaneous methoxy
Roger SD, Wong CM, Vejakama P, Rahardjo KD, Hsu BG, Lee CM, Wu IW, Lee CC, Situmorang TD, Krisanapan P, Mazlan SA, Peng YS, Sarwono J, De Asis N, Solimen D, Jonny, Sangthawan P, Chen JB, Wang CL, Chung S, Villaflor AJ, Yang CW, Kan WC, Yang Y, Rubio-Bicol J, Yan LY, Lee SH, Chiu YW, Chen CH, Na KY, Hassah WHHW, Kang YS, Choi BS, Aquitania G, Na KR, Wu MS, Ahmad MK, Isidto R, Wu V, Leong GB, Sung JM, Noppakun K, Chou KJ, Abdul Wahab MZ, Shin SJ, Nugroho P.   +45 more
europepmc   +2 more sources

Epoetin Alfa

Reactions Weekly
Vest LS, Patel P, Patel JB.
europepmc   +6 more sources

Epoetin alfa [PDF]

Reactions Weekly, 2004
Recombinant human erythropoietin (epoetin alfa) has been used in clinical settings for more than a decade. Its indications have expanded considerably from its original use as hormone therapy in the treatment of anemia in adults with chronic kidney disease. Since the introduction of epoetin alfa, a greater understanding of anemia pathophysiology and the
David H, Henry, Peter, Bowers, Michael T, Romano, Robert, Provenzano   +3 more
  +5 more sources

COST-MINIMIZATION ANALYSIS OF USING SHORT AND LONG-ACTING ERYTHROPOESIS-STIMULATING AGENTS FOR CORRECTION OF NEPHROGENIC ANEMIA AGAINST THE BACKGROUND OF SUBSTITUTION THERAPY

Фармация и фармакология (Пятигорск), 2021
Clinical trials conducted in various countries indicate that the use of epoetin alfa in patients with nephrogenic anemia in chronic kidney disease can increase the effectiveness of treatment, reduce the incidence of cardiovascular and infectious ...
I. S. Krysanov, E. Yu. Ermakova, L. B. Vaskova, M. V. Tiapkina   +3 more
doaj   +1 more source

THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY

Hematology, Transfusion and Cell Therapy, 2023
Objective: This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting.
Müzeyyen Aslaner Ak, Birsen Sahip, Ayfer Geduk, Mehmet Ali Uçar, Hacer Kale, Tugba Hacibekiroglu, Merve Gokcen Polat, Yasin Kalpakcı, Ali Zahit Bolaman, Birol Guvenc, Sehmus Ertop   +10 more
doaj   +1 more source

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

Turkish Journal of Hematology, 2023
Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk or
Müzeyyen Aslaner Ak, Ayfer Gedük, İbrahim Halil Açar, Merve Gökçen Polat, Cenk Sunu, Ali Zahit Bolaman, Tuba Hacıbekiroğlu, Birol Güvenç, Şehmus Ertop   +8 more
doaj   +1 more source

Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trialResearch in context

EClinicalMedicine, 2023
Summary: Background: Pegmolesatide, a synthetic peptide-based erythropoietin (EPO) receptor agonist, is being evaluated as an alternative to epoetin alfa for treating anemia of chronic kidney disease (CKD) in Chinese dialysis patients.
Ping Zhang, Yan Jiang, Chunping Xu, Linghui Zhou, Hongguang Zheng, Deqiong Xie, Minghao Guo, Xiangyang Huang, Guoyuan Lu, Hongli Jiang, Hongyu Qiu, Bicheng Liu, Shaomei Li, Qinkai Chen, Yu'ou Xia, Bengui Sun, Xiao Yang, Shiying Zhang, Shutong Du, Mindan Sun, Menghua Chen, Aimin Zhong, Xiaoling Wang, Zhanzheng Zhao, Hua Zhou, Guisen Li, Yueqin Ren, Qun Luo, Aicheng Yang, Ping Luo, Shuifu Tang, Chengyun Xu, Qin Wang, Xiaoxia Wang, Tiekun Yan, Wei He, Shuguang Qin, Weili Zhang, Lu Lv, Cheng Wang, Hong Liu, Jing Li, Qiong Wu, Chao Pan, Chuan Li, Liangliang He, Jianghua Chen   +46 more
doaj   +1 more source

Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients

Медицинский совет, 2021
Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign.
I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova   +2 more
doaj   +1 more source

Epoetin Alfa

Reactions Weekly, 2006
europepmc   +2 more sources

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]

, 2013
BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du, Hinke, Axel, Huober, Jens, Jackisch, Christian, Kreienberg, Rolf, Kuhn, Walther, Kurbacher, Christian, Lueck, Hans-Joachim, Moebus, Volker, Nitz, Ulrike, Runnebaum, Ingo B., Schneeweiss, Andreas, Thomssen, Christoph, Untch, Michael   +13 more
core   +1 more source